ALPMY - Astellas Pharma Inc.
| Previous Close | 13.43 |
| Open | 13.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 13.25 - 13.40 |
| 52 Week Range | 11.82 - 15.22 |
| Volume | 673 |
| Avg. Volume | 84,653 |
| Market Cap | 27.62B |
| Beta | 0.35 |
| PE Ratio (TTM) | 15.80 |
| EPS (TTM) | 0.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.30 (2.32%) |
| Ex-Dividend Date | 2016-09-27 |
| 1y Target Est | N/A |
Capital Cube•27 minutes agoAstellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 1.87 percent and its dividend payout is percent. This compares to ... Read more (Read more...)
- PR Newswire•4 days ago
Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology
TOKYO, Oct. 19, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Universal Cells, Inc. (CEO: Claudia Mitchell, "Universal Cells") today announced that Astellas Institute for Regenerative Medicine ("AIRM") and Universal Cells have entered into an exclusive worldwide license agreement to research, develop and commercialize a novel cell therapy for an undisclosed indication. The collaboration will utilize Universal Cells' Universal Donor Cell technology to create cell therapy products that can be administered to any recipient without the need for Human Leukocyte Antigen (HLA) matching.
- Zacks•10 days ago
Cancer Space Update: Lung & Breast Cancer Studies in Focus
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
- PR Newswire•13 days ago
U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia
TOKYO, Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of gilteritinib for adult patients with FLT3 mutation-positive (FLT3+) relapsed or refractory acute myeloid leukemia (AML). Fast Track designation is designed to facilitate the development, and expedite the FDA review, of drugs to treat serious and life-threatening conditions so that, if approved, the compounds can reach the market expeditiously.
- PR Newswire•13 days ago
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (SGEN) today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy. The EV-201 study will assess the antitumor activity and safety of enfortumab vedotin to support potential registration under the U.S. Food and Drug Administration's (FDA) accelerated approval regulations. In addition, there are no FDA-approved therapies for patients who progress following CPI treatment," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics.
Capital Cube•17 days agoAstellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 0.85 percent and its dividend payout is percent. This compares to ... Read more (Read more...)
- Zacks•last month
Why Did Pfizer (PFE) Stock Pop Today?
Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.
- Reuters•last month
Pfizer, Astellas prostate cancer drug promising in late-stage trial
Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body.
- Reuters•last month
UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial
Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease. The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for Pfizer.
- PR Newswire•last month
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
- Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical ...
- PR Newswire•last month
U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
TOKYO, Sept. 12, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) that seeks approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The anticipated Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 28, 2018.
- Capital Cube•2 months ago
ETFs with exposure to Astellas Pharma, Inc. : August 28, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•2 months ago
First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
TOKYO, Aug. 21, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the fourth Phase 3 trial underway in the gilteritinib clinical development program. The MORPHO trial is a randomized, double-blind, placebo-controlled, multi-center trial that compares gilteritinib to placebo as maintenance therapy over a period of two years following hematopoietic stem cell transplant (HCT) in patients with FLT3 internal tandem duplication (ITD) mutation-positive (FLT3/ITD+) acute myeloid leukemia (AML) and in remission after induction therapy.
Capital Cube•2 months agoAstellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017
Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (JNJ-US, MRK-US, PFE-US, AMGN-US and VICL-US) that have also reported ... Read more (Read more...)
- Capital Cube•2 months ago
ETFs with exposure to Astellas Pharma, Inc. : August 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•3 months ago
Astellas Announces Wind-Down of Agensys Research Operations
TOKYO, July 26, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that it is winding down its Agensys research operations in Santa Monica, California, USA, to further refine its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus on Antibody-Drug Conjugate (ADC) research. "Agensys has positively contributed to Astellas' objective of developing innovative treatments for patients with cancer," said Wataru Uchida, Ph.D., senior vice president, Drug Discovery Research (DDR), Astellas.
- PR Newswire•3 months ago
U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
TOKYO, July 20, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation to gilteritinib in patients with acute myeloid leukemia (AML). "Fewer than 10,000 Americans will be diagnosed with FLT3 mutation-positive AML this year and while that may be a small percentage of the overall population, it is an important group of patients who are deserving of potential new treatments," said Steven Benner, M.D., senior vice president and global therapeutic area head, oncology development, Astellas.
- Capital Cube•3 months ago
ETFs with exposure to Astellas Pharma, Inc. : July 10, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•4 months ago
Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
TOKYO, June 29, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. In the United States, mirabegron and solifenacin succinate are marketed as Myrbetriq® and VESIcare®, respectively.
- Capital Cube•4 months ago
ETFs with exposure to Astellas Pharma, Inc. : June 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•4 months agoAstellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q4, 2017 By the Numbers : June 21, 2017
Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (MRK-US, PFE-US, AMGN-US and VICL-US) that have also reported for this period. Highlights ... Read more (Read more...)
- Zacks•4 months ago
Seattle Genetics Halts Phase III Study on Leukemia Drug
Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.
- PR Newswire•4 months ago
The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants
TOKYO, June 20, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) (President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the launch of the second year of the Astellas C3 Prize, a global challenge designed to change cancer care by inspiring non-medicine innovations that may improve the lives of patients with cancer, their caregivers and their loved ones. Entries will be accepted through August 21st and five finalists will be selected to pitch their ideas live at the Union for International Cancer Control (UICC) World Cancer Leaders' Summit on November 13th in Mexico City.
- PR Newswire•4 months ago
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
TOKYO and NEW YORK, June 9, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Pfizer Inc. (PFE) announced today the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI (enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). "XTANDI is already a standard of care for men worldwide fighting metastatic castration-resistant prostate cancer, but we are continually looking to evaluate this medicine for men facing earlier stage disease," said Steven Benner, M.D., senior vice president and global therapeutic area head, oncology development, Astellas.
